We are live on
!
Find out more
AACR
ACR Alpine Capital Research Portfolio holdings
AUM
$6.7B
1-Year Est. Return
33.44%
This Fund
S&P 500
This Quarter
Est. Return
+3.4%
1 Year Est. Return
+33.44%
3 Year Est. Return
+61.38%
5 Year Est. Return
+53.14%
10 Year Est. Return
+201.58%
AUM
$670M
AUM Growth
+$16.4M
(+2.5%)
Cap. Flow
-$8.5M
Cap. Flow
% of AUM
-1.27%
Top 10 Holdings %
Top 10 Hldgs %
88.77%
Holding
27
New
1
Increased
9
Reduced
4
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ESRX
Express Scripts Holding Company
ESRX
|
+$38.5M |
| 2 |
Vodafone
VOD
|
+$4.66M |
| 3 |
Humana
HUM
|
+$4.15M |
| 4 |
Johnson & Johnson
JNJ
|
+$4.06M |
| 5 |
Walmart Inc
WMT
|
+$3.65M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Intel
INTC
|
+$41.3M |
| 2 |
Lockheed Martin
LMT
|
+$29.3M |
| 3 |
Microsoft
MSFT
|
+$429K |
| 4 |
Teva Pharmaceuticals
TEVA
|
+$351K |
| 5 |
Berkshire Hathaway Class B
BRK.B
|
+$316K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 37.48% |
| 2 | Consumer Staples | 16.39% |
| 3 | Technology | 16.33% |
| 4 | Financials | 15.07% |
| 5 | Communication Services | 8.86% |
Similar funds
MSE
MIP
FLPIM
BHM
SPS
SPC
TAM
TB
ACR Alpine Capital Research's Q3 2014 Portfolio in Review
As of Q3 2014, ACR Alpine Capital Research held 27 positions worth $670M, up 2.5% from $654M the previous quarter. Its ten largest holdings account for 89% of the portfolio.
ACR Alpine Capital Research's Q3 2014 filing shows 1 new, 9 increased, 4 reduced and 4 closed positions. Its largest new stake was Express Scripts Holding Company: 541,005 shares worth $38.2M. The largest sale was Intel, an estimated $41.3M.
By sector, the portfolio is most concentrated in Healthcare at 37% of assets, up from 30% a quarter earlier, followed by Consumer Staples and Technology.
- ACR Alpine Capital Research's largest Q3 2014 buy was Express Scripts Holding Company: 541,005 shares worth $38.2M.
- ACR Alpine Capital Research added most to Vodafone in Q3 2014, an estimated $4.66M increase.
- ACR Alpine Capital Research's biggest Q3 2014 reduction was Intel, cutting an estimated $41.3M.
- ACR Alpine Capital Research fully exited Teva Pharmaceuticals in Q3 2014, selling an estimated $351K.
- ACR Alpine Capital Research's ten largest holdings make up 89% of its $670M portfolio in Q3 2014.
- ACR Alpine Capital Research opened 1 new position and closed 4 in Q3 2014.
- ACR Alpine Capital Research's portfolio value rose 2.5% quarter-over-quarter to $670M.
Based on ACR Alpine Capital Research's 13F filing for Q3 2014, filed 12 Nov 2014.